Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Chelsea Therapeutics International, Ltd. Stockholders
09 Maggio 2014 - 12:35AM
Business Wire
Kirby McInerney LLP is investigating potential claims against
the Board of Directors of Chelsea Therapeutics International, Ltd.
(“Chelsea Therapeutics” or the “Company”) (NASDAQ: CHTP) concerning
the proposed acquisition of the Company by H. Lundbeck A/S
(“Lundbeck”). Under the terms of the definitive merger agreement,
Chelsea Therapeutics stockholders will receive $6.44 in cash and up
to $1.50 in Contingent Value Rights for each share of Chelsea
Therapeutics owned, representing a total potential consideration of
up to $658 million.
The investigation concerns whether the Chelsea Therapeutics
Board of Directors violated its fiduciary duties by agreeing to the
proposed transaction and whether the proposed consideration
adequately values Chelsea Therapeutics’ common stock.
If you are a Chelsea Therapeutics stockholder and wish to obtain
additional information, please contact J. Brandon Walker, Esq.
by email at bwalker@kmllp.com, by telephone at (212) 699-1145 or
(888) 529-4787, or by filling out this contact form. There is no
cost or obligation to you.
Kirby McInerney LLP is a New York-based law firm concentrating
in securities, shareholder, whistleblower, antitrust and consumer
litigation. For additional information, please go to
www.kmllp.com.
Kirby McInerney LLPJ. Brandon Walker, Esq.212-699-1145 /
888-529-4787bwalker@kmllp.com
Grafico Azioni Chelsea Therapeutics International, Ltd. (MM) (NASDAQ:CHTP)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Chelsea Therapeutics International, Ltd. (MM) (NASDAQ:CHTP)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Chelsea Therapeutics International, Ltd. (MM) (NASDAQ): 0 articoli recenti
Più Chelsea Therapeutics International, Ltd. (MM) Articoli Notizie